Literature DB >> 9742941

On the expression of cytosolic calcium-independent phospholipase A2 (88kDa) in immature and mature myeloid cells and its role in leukotriene synthesis in human granulocytes.

P K Larsson Forsell1, G Runarsson, M Ibrahim, M Björkholm, H E Claesson.   

Abstract

The human calcium-independent phospholipase A2 (iPLA2; 88 kDa) has recently been cloned (Larsson, P.K.A., Claesson, H.-E. and Kennedy, B.P. (1998) J. Biol. Chem. 272, 207-214). Here we demonstrate the expression of the human iPLA2 mRNA and its splice variants in blood progenitor cells, immature leukemic cells and mature granulocytes. Chromatographical resolvable iPLA2 activity was found in the cytosolic fraction of granulocytes and the activity was inhibited by the iPLA2 inhibitor bromoenol lactone. This drug also inhibited leukotriene synthesis in human granulocytes, induced by low concentration of calcium ionophore A23187 (0.10-0.15 microM) or opsonized zymosan. These results suggest that iPLA2 is involved in the regulation of the pool of arachidonic acid destined for leukotriene synthesis in human granulocytes.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9742941     DOI： 10.1016/s0014-5793(98)00999-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  9 in total

1.  Polychlorinated biphenyls induce arachidonic acid release in human platelets in a tamoxifen sensitive manner via activation of group IVA cytosolic phospholipase A2-alpha.

Authors:  Pontus K A Forsell; Anders O Olsson; Erik Andersson; Laxman Nallan; Michael H Gelb
Journal:  Biochem Pharmacol       Date:  2005-11-14       Impact factor: 5.858

2.  Insulin secretory responses and phospholipid composition of pancreatic islets from mice that do not express Group VIA phospholipase A2 and effects of metabolic stress on glucose homeostasis.

Authors:  Shunzhong Bao; Haowei Song; Mary Wohltmann; Sasanka Ramanadham; Wu Jin; Alan Bohrer; John Turk
Journal:  J Biol Chem       Date:  2006-05-27       Impact factor: 5.157

3.  iPLA2 Activation Mediates Granular Exocytosis and Corrects Microbicidal Defects in ROS-Deficient and CGD Human Neutrophils.

Authors:  Issam Harfi; Stéphanie D'Hondt; Eric Sariban
Journal:  J Clin Immunol       Date:  2019-06-01       Impact factor: 8.317

4.  Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1.

Authors:  Z Ma; X Wang; W Nowatzke; S Ramanadham; J Turk
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

5.  Effects of stable suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells.

Authors:  Shunzhong Bao; Alan Bohrer; Sasanka Ramanadham; Wu Jin; Sheng Zhang; John Turk
Journal:  J Biol Chem       Date:  2005-11-14       Impact factor: 5.157

6.  Studies of phospholipid metabolism, proliferation, and secretion of stably transfected insulinoma cells that overexpress group VIA phospholipase A2.

Authors:  Z Ma; A Bohrer; M Wohltmann; S Ramanadham; F F Hsu; J Turk
Journal:  Lipids       Date:  2001-07       Impact factor: 1.880

7.  Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2.

Authors:  Karin Killermann Lucas; Camilla I Svensson; Xiao-Ying Hua; Tony L Yaksh; Edward A Dennis
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 8.  Calcium-independent phospholipases A2 and their roles in biological processes and diseases.

Authors:  Sasanka Ramanadham; Tomader Ali; Jason W Ashley; Robert N Bone; William D Hancock; Xiaoyong Lei
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

9.  Roles of various phospholipases A2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling.

Authors:  Jesús Balsinde
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.